دورية أكاديمية
أعرض في EDS

Piracetam reduces oxidative stress and mitochondrial function impairment in an in vitro model of vascular dementia.

التفاصيل البيبلوغرافية
العنوان: Piracetam reduces oxidative stress and mitochondrial function impairment in an in vitro model of vascular dementia.
المؤلفون: Liu J; Department of Neurology, The First Affiliated Hospital of Xi'an Medical University, No.48 FengHao Road(West), Lianhu District, Xi'an City, 710077, Shaanxi Province, China. jliu9667@163.com., Yang N; Department of Neurology, The First Affiliated Hospital of Xi'an Medical University, No.48 FengHao Road(West), Lianhu District, Xi'an City, 710077, Shaanxi Province, China., Wang X; Department of Neurology, The First Affiliated Hospital of Xi'an Medical University, No.48 FengHao Road(West), Lianhu District, Xi'an City, 710077, Shaanxi Province, China., Wang W; Department of Neurology, The First Affiliated Hospital of Xi'an Medical University, No.48 FengHao Road(West), Lianhu District, Xi'an City, 710077, Shaanxi Province, China.
المصدر: Experimental brain research [Exp Brain Res] 2024 Aug; Vol. 242 (8), pp. 1841-1850. Date of Electronic Publication: 2024 Jun 06.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 0043312 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-1106 (Electronic) Linking ISSN: 00144819 NLM ISO Abbreviation: Exp Brain Res Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Berlin : Springer Verlag
مواضيع طبية MeSH: Oxidative Stress*/drug effects , Oxidative Stress*/physiology , Dementia, Vascular*/drug therapy , Dementia, Vascular*/metabolism , Piracetam*/pharmacology , Mitochondria*/drug effects , Mitochondria*/metabolism, Humans ; Cell Line, Tumor ; Neuroprotective Agents/pharmacology ; Glucose/metabolism ; Dose-Response Relationship, Drug
مستخلص: Vascular dementia (VaD) is the most common cause of dementia in older adults. Due to the lack of effective treatment options, there is an urgent need to find an effective pharmaceutical compound to combat VaD. Piracetam has been reported to improve impaired cognitive function in a variety of conditions in both human and animal models. However, the role and mechanism of Piracetam in VaD remain unclear. Therefore this study aimed to elucidate the effect of Piracetam on a cellular model of VaD in vitro. We found that Piracetam enhanced the growth of OGD-stimulated SH-SY5Y cells. In addition, Piracetam inhibited the oxidative stress of OGD-stimulated SH-SY5Y cells. Further, Piracetam improved mitochondrial function of OGD-stimulated SH-SY5Y cells. Mechanistically, Piracetam inhibited the PI3K/Akt/mTOR pathway in OGD-stimulated SH-SY5Y cells. Collectively, Piracetam improved oxidative stress and mitochondrial dysfunction of OGD-stimulated SH-SY5Y cells through PI3K/Akt/mTOR axis. Hence, Piracetam has the potential to serve as a promising drug of VaD.
(© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
References: Cohen PA, Zakharevich I, Gerona R (2020) Presence of Piracetam in Cognitive Enhancement Dietary supplements. JAMA Intern Med 180:458–459. https://doi.org/10.1001/jamainternmed.2019.5507. (PMID: 10.1001/jamainternmed.2019.550731764936)
Dichgans M, Leys D (2017) Vascular cognitive impairment. Circ Res 120:573–591. https://doi.org/10.1161/CIRCRESAHA.116.308426. (PMID: 10.1161/CIRCRESAHA.116.30842628154105)
Du SQ, Wang XR, Xiao LY, Tu JF, Zhu W, He T, Liu CZ (2017) Molecular mechanisms of vascular dementia: what can be learned from animal models of chronic cerebral hypoperfusion? Mol Neurobiol. 54:3670–3682. https://doi.org/10.1007/s12035-016-9915-1.
Guan T, Xiao Y, Xie X, Meng N, Qi Q, Xu J, Lv P (2023) Dulaglutide improves gliosis and suppresses Apoptosis/Autophagy through the PI3K/Akt/mTOR signaling pathway in vascular dementia rats. Neurochem Res 48:1561–1579. https://doi.org/10.1007/s11064-022-03853-0. (PMID: 10.1007/s11064-022-03853-036571662)
Hall ED, Von Voigtlander PF (1987) Facilitatory effects of piracetam on excitability of motor nerve terminals and neuromuscular transmission. Neuropharmacology 26:1573–1579. https://doi.org/10.1016/0028-3908(87)90003-7. (PMID: 10.1016/0028-3908(87)90003-72829047)
Hosoki S, Hansra GK, Jayasena T, Poljak A, Mather KA, Catts VS, Sachdev PS (2023) Molecular biomarkers for vascular cognitive impairment and dementia. Nat Rev Neurol 19:737–753. https://doi.org/10.1038/s41582-023-00884-1. (PMID: 10.1038/s41582-023-00884-137957261)
Keil U, Scherping I, Hauptmann S, Schuessel K, Eckert A, Muller WE (2006) Piracetam improves mitochondrial dysfunction following oxidative stress. Br J Pharmacol 147:199–208. https://doi.org/10.1038/sj.bjp.0706459. (PMID: 10.1038/sj.bjp.070645916284628)
Li X, Ren C, Li S, Han R, Gao J, Huang Q, Ji X (2017) Limb remote ischemic conditioning promotes myelination by upregulating PTEN/Akt/mTOR signaling activities after chronic cerebral hypoperfusion. Aging Dis 8:392–401. https://doi.org/10.14336/AD.2016.1227. (PMID: 10.14336/AD.2016.1227288400545524802)
Luan Y, Luan Y, Jiao Y, Liu H, Huang Z, Feng Q, Ren K (2023) Broadening Horizons: exploring mtDAMPs as a mechanism and potential intervention target in Cardiovascular diseases. Aging Dis. https://doi.org/10.14336/AD.2023.1130. (PMID: 10.14336/AD.2023.11303827011810389826)
Malykh AG, Sadaie MR (2010) Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders. Drugs 70:287–312. https://doi.org/10.2165/11319230-000000000-00000. (PMID: 10.2165/11319230-000000000-0000020166767)
Mindus P, Cronholm B, Levander SE, Schalling D (1976) Piracetam-induced improvement of mental performance. A controlled study on normally aging individuals. Acta Psychiatr Scand 54:150–160. https://doi.org/10.1111/j.1600-0447.1976.tb00107.x. (PMID: 10.1111/j.1600-0447.1976.tb00107.x785952)
Muley MM, Thakare VN, Patil RR, Bafna PA, Naik SR (2013) Amelioration of cognitive, motor and endogenous defense functions with silymarin, piracetam and protocatechuic acid in the cerebral global ischemic rat model. Life Sci 93:51–57. https://doi.org/10.1016/j.lfs.2013.05.020. (PMID: 10.1016/j.lfs.2013.05.02023743171)
Nasr M, Wahdan SA (2019) Neuroprotective effects of novel nanosystems simultaneously loaded with vinpocetine and piracetam after intranasal administration. Life Sci 226:117–129. https://doi.org/10.1016/j.lfs.2019.04.014. (PMID: 10.1016/j.lfs.2019.04.01430981765)
O’Brien JT, Thomas A (2015) Vascular dementia. Lancet 386:1698–1706. https://doi.org/10.1016/S0140-6736(15)00463-8. (PMID: 10.1016/S0140-6736(15)00463-826595643)
Rajeev V, Fann DY, Dinh QN, Kim HA, De Silva TM, Lai MK, P, Arumugam TV (2022) Pathophysiology of blood brain barrier dysfunction during chronic cerebral hypoperfusion in vascular cognitive impairment. Theranostics 12:1639–1658. https://doi.org/10.7150/thno.68304. (PMID: 10.7150/thno.68304351980628825579)
Verma DK, Gupta S, Biswas J, Joshi N, Singh A, Gupta P, Singh S (2018) New therapeutic activity of metabolic enhancer piracetam in treatment of neurodegenerative disease: participation of caspase independent death factors, oxidative stress, inflammatory responses and apoptosis. Biochim Biophys Acta Mol Basis Dis 1864:2078–2096. https://doi.org/10.1016/j.bbadis.2018.03.014. (PMID: 10.1016/j.bbadis.2018.03.01429551729)
Wolters FJ, Ikram MA (2019) Epidemiology of vascular dementia. Arterioscler Thromb Vasc Biol 39:1542–1549. https://doi.org/10.1161/ATVBAHA.119.311908. (PMID: 10.1161/ATVBAHA.119.31190831294622)
Xiao H, Peng D, Guo YJE, J o G, O (2023) CENPF facilitates endometrial cancer cell progression through PI3K/AKT/mTOR pathway. Eur J Gynaecol Oncol 44:106–114.
Xu P, Li M, Bai Y, Lu W, Ling X, Li W (2015) The effects of piracetam on heroin-induced CPP and neuronal apoptosis in rats. Drug Alcohol Depend 150:141–146. https://doi.org/10.1016/j.drugalcdep.2015.02.026. (PMID: 10.1016/j.drugalcdep.2015.02.02625801591)
فهرسة مساهمة: Keywords: OGD; Oxidative stress; PI3K/Akt/mTOR axis; Piracetam; Vascular dementia (VaD)
المشرفين على المادة: ZH516LNZ10 (Piracetam)
0 (Neuroprotective Agents)
IY9XDZ35W2 (Glucose)
تواريخ الأحداث: Date Created: 20240606 Date Completed: 20240716 Latest Revision: 20240716
رمز التحديث: 20240716
DOI: 10.1007/s00221-024-06868-x
PMID: 38842755
قاعدة البيانات: MEDLINE
الوصف
تدمد:1432-1106
DOI:10.1007/s00221-024-06868-x